Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 烟台东诚药业集团股份有限公司属于医药制造业,主营业务为肝素钠原料药、硫酸软骨素的研发、生产和销售,主要产品一直为肝素钠原料药、硫酸软骨素.此外,本公司还生产细胞色素C原料,以及注射用尿促性素、注射用绒促性素等药物制剂.公司目前共拥有36个药品生产批准文号,正在申请的还有9项,涵盖原料药、注射剂等剂型,主要产品所处的细分行业为生化原料药行业,2000年,本公司通过SFDA的GMP认证;2001年5月,公司通过了挪威船级社(DNV)的ISO9000:1994质量体系认证,经过2003和2006年两次换证审核后,本公司于2009年4月又通过了挪威船级社(DNV)的ISO9001:2008换证审核;2004年起,公司陆续通过了德国汉堡BSG(BGV)、美国药典委员会和美国FDA的GMP现场检查等。
Main Business 肝素钠原料药、硫酸软骨素的研发、生产和销售。
Legal Representative 由守谊
Top Executives
董事长：由守谊
董事：刘晓杰,罗志刚
独立董事：赵大勇,李方
Top 5 Shareholder
Shareholder name Nature Holding Date
烟台东益生物工程有限公司流通A股15.15%31/03/2025
由守谊限售股+流通A股12.53%31/03/2025
石雯流通A股3.94%31/03/2025
PACIFIC RAINBOW INTERNATIONA L,INC.流通A股3.35%31/03/2025
上海高毅资产管理合伙企业（有限合伙）－高毅邻山1号远望基金流通A股2.61%31/03/2025
Company Secretary 刘晓杰
Solicitors 北京市中伦律师事务所
Auditors 中天运会计师事务所（特殊普通合伙）
Tel No 0535-6371119
Fax No 0535-6371119
Website www.dcb-group.com
Email stock@dcb-group.com
Company Address
Register: 山东省烟台市经济技术开发区长白山路7号
Office: 山东省烟台市经济技术开发区长白山路7号
Listing Date 25/05/2012
Shares Capital
Shares Capital: 824,595,705
Total A Share: 824,595,705
Listed A Share: 743,383,994
Non-tradable A Share: 81,211,711
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.223
DPS(RMB)* ¥ 0.080
NBV Per Share(RMB)* ¥ 5.434
Market Capitalization(RMB) 10.861B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.